Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

CHR-2797

120mg once daily oral for 48 weeks

Trial Locations (6)

10021

New York Presbyterian Hospitacl, New York

27710

Duke University Medical Center, Durham

90095

UCLA Division of Hematology/Oncology, Los Angeles

48109-2800

University of Michigan, Ann Arbor

07601

John Theurer Cancer Center, Hackensack

77030-4009

MD Anderson, Houston

Sponsors
All Listed Sponsors
lead

Chroma Therapeutics

INDUSTRY

NCT01180426 - Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter